Manhattan Scientifics Seed Funded Imagion Bioscience & Owns 64 Million Shares IBX
NEW YORK--(BUSINESS WIRE)--Jul 25, 2019--
Manhattan Scientifics (OTC; QB MHTX) announces its former wholly owned sub Imagion Bioscience (ASX:IBX) Receives A$2 million in R&D Tax Incentives from the Australian Government (ATO)
Bob Proulx, Executive Chairman of Imagion Biosystems, said: “We are very pleased to report to our shareholders that the tax incentive funds have been received and that the rebate came in higher than the A$1.7 million we originally expected. This cash infusion will significantly enhance our ability to advance the development of our ground-breaking diagnostic imaging technology which was recently designated by the U.S. Food and Drug Administration as a ‘Breakthrough Device’”.
About Manhattan Scientifics Inc.
Manhattan Scientifics is focused on the commercialization of disruptive technologies
This press release contains forward looking statements which are subject 5to a number of risks, assumptions and uncertainties. Mgt believes that purchase of our shares should be considered to be at the high end of the risk spectrum.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190725005680/en/
CONTACT: Marvin Maslow, Chairman: 917.923.3300
Manny Tsoupanarias, CEO : 917.688.4158
KEYWORD: NEW YORK NORTH AMERICA UNITED STATES AUSTRALIA/OCEANIA AUSTRALIA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL ONCOLOGY HEALTH MEDICAL DEVICES OTHER HEALTH
SOURCE: Manhattan Scientifics
Copyright Business Wire 2019.
PUB: 07/25/2019 01:55 PM/DISC: 07/25/2019 01:55 PM